Adage Capital Partners Gp, L.L.C. C4 Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,550,000 shares of CCCC stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,550,000
Previous 1,550,000
-0.0%
Holding current value
$2.33 Million
Previous $5.58 Million
55.56%
% of portfolio
0.0%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding CCCC
# of Institutions
118Shares Held
63.1MCall Options Held
18.8KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR7.1MShares$10.6 Million4.2% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$10.5 Million0.92% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$10.2 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.72MShares$10.1 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$6.83 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $73.4M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...